Literature DB >> 24512192

NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Becky A Diebold1, Susan M E Smith2, Yang Li1, J David Lambeth1.   

Abstract

SIGNIFICANCE: NOX2 is important for host defense, and yet is implicated in a large number of diseases in which inflammation plays a role in pathogenesis. These include acute and chronic lung inflammatory diseases, stroke, traumatic brain injury, and neurodegenerative diseases, including Alzheimer's and Parkinson's Diseases. RECENT ADVANCES: Recent drug development programs have targeted several NOX isoforms that are implicated in a variety of diseases. The focus has been primarily on NOX4 and NOX1 rather than on NOX2, due, in part, to concerns about possible immunosuppressive side effects. Nevertheless, NOX2 clearly contributes to the pathogenesis of many inflammatory diseases, and its inhibition is predicted to provide a novel therapeutic approach. CRITICAL ISSUES: Possible side effects that might arise from targeting NOX2 are discussed, including the possibility that such inhibition will contribute to increased infections and/or autoimmune disorders. The state of the field with regard to existing NOX2 inhibitors and targeted development of novel inhibitors is also summarized. FUTURE DIRECTIONS: NOX2 inhibitors show particular promise for the treatment of inflammatory diseases, both acute and chronic. Theoretical side effects include pro-inflammatory and autoimmune complications and should be considered in any therapeutic program, but in our opinion, available data do not indicate that they are sufficiently likely to eliminate NOX2 as a drug target, particularly when weighed against the seriousness of many NOX2-related indications. Model studies demonstrating efficacy with minimal side effects are needed to encourage future development of NOX2 inhibitors as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24512192      PMCID: PMC4545678          DOI: 10.1089/ars.2014.5862

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  339 in total

1.  Regulation of proliferation of skeletal muscle precursor cells by NADPH oxidase.

Authors:  Mahroo Mofarrahi; Ralf P Brandes; Agnes Gorlach; Joerg Hanze; Lance S Terada; Mark T Quinn; Dominique Mayaki; Basil Petrof; Sabah N A Hussain
Journal:  Antioxid Redox Signal       Date:  2008-03       Impact factor: 8.401

Review 2.  Reactive oxygen species production in the phagosome: impact on antigen presentation in dendritic cells.

Authors:  Fiorella Kotsias; Eik Hoffmann; Sebastian Amigorena; Ariel Savina
Journal:  Antioxid Redox Signal       Date:  2012-09-11       Impact factor: 8.401

3.  Reconstitution of bactericidal activity in chronic granulomatous disease cells by glucose-oxidase-containing liposomes.

Authors:  C E Gerber; G Bruchelt; U B Falk; A Kimpfler; O Hauschild; S Kuçi; T Bächi; D Niethammer; R Schubert
Journal:  Blood       Date:  2001-11-15       Impact factor: 22.113

4.  Inhibition by magnolol of formylmethionyl-leucyl-phenyl alanine-induced respiratory burst in rat neutrophils.

Authors:  J P Wang; M F Hsu; S L Raung; L C Chang; L T Tsao; P L Lin; C C Chen
Journal:  J Pharm Pharmacol       Date:  1999-03       Impact factor: 3.765

5.  Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2.

Authors:  Gábor Csányi; Eugenia Cifuentes-Pagano; Imad Al Ghouleh; Daniel J Ranayhossaini; Loreto Egaña; Lucia R Lopes; Heather M Jackson; Eric E Kelley; Patrick J Pagano
Journal:  Free Radic Biol Med       Date:  2011-04-17       Impact factor: 7.376

Review 6.  NADPH oxidase-dependent signaling in endothelial cells: role in physiology and pathophysiology.

Authors:  Randall S Frey; Masuko Ushio-Fukai; Asrar B Malik
Journal:  Antioxid Redox Signal       Date:  2009-04       Impact factor: 8.401

7.  Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase.

Authors:  H X Deng; A Hentati; J A Tainer; Z Iqbal; A Cayabyab; W Y Hung; E D Getzoff; P Hu; B Herzfeldt; R P Roos
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

Review 8.  NADPH oxidases: functions and pathologies in the vasculature.

Authors:  Bernard Lassègue; Kathy K Griendling
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-11-12       Impact factor: 8.311

9.  Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease.

Authors:  Luigina Romani; Francesca Fallarino; Antonella De Luca; Claudia Montagnoli; Carmen D'Angelo; Teresa Zelante; Carmine Vacca; Francesco Bistoni; Maria C Fioretti; Ursula Grohmann; Brahm H Segal; Paolo Puccetti
Journal:  Nature       Date:  2008-01-10       Impact factor: 49.962

10.  The p47phox mouse knock-out model of chronic granulomatous disease.

Authors:  S H Jackson; J I Gallin; S M Holland
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

View more
  25 in total

1.  A combination antioxidant therapy to inhibit NOX2 and activate Nrf2 decreases secondary brain damage and improves functional recovery after traumatic brain injury.

Authors:  Raghavendar Chandran; TaeHee Kim; Suresh L Mehta; Eshwar Udho; Vishal Chanana; Pelin Cengiz; HwuiWon Kim; Chanul Kim; Raghu Vemuganti
Journal:  J Cereb Blood Flow Metab       Date:  2017-10-30       Impact factor: 6.200

2.  High-Throughput Screening of NOX Inhibitors.

Authors:  Jacek Zielonka; Monika Zielonka; Gang Cheng; Micael Hardy; Balaraman Kalyanaraman
Journal:  Methods Mol Biol       Date:  2019

3.  Glucose-6-phosphate dehydrogenase inhibition attenuates acute lung injury through reduction in NADPH oxidase-derived reactive oxygen species.

Authors:  A Nadeem; N O Al-Harbi; S F Ahmad; K E Ibrahim; N Siddiqui; M M Al-Harbi
Journal:  Clin Exp Immunol       Date:  2018-01-21       Impact factor: 4.330

4.  Discovery of GSK2795039, a Novel Small Molecule NADPH Oxidase 2 Inhibitor.

Authors:  Kazufumi Hirano; Woei Shin Chen; Adeline L W Chueng; Angela A Dunne; Tamara Seredenina; Aleksandra Filippova; Sumitra Ramachandran; Angela Bridges; Laiq Chaudry; Gary Pettman; Craig Allan; Sarah Duncan; Kiew Ching Lee; Jean Lim; May Thu Ma; Agnes B Ong; Nicole Y Ye; Shabina Nasir; Sri Mulyanidewi; Chiu Cheong Aw; Pamela P Oon; Shihua Liao; Dizheng Li; Douglas G Johns; Neil D Miller; Ceri H Davies; Edward R Browne; Yasuji Matsuoka; Deborah W Chen; Vincent Jaquet; A Richard Rutter
Journal:  Antioxid Redox Signal       Date:  2015-08-10       Impact factor: 8.401

Review 5.  Peroxiredoxins and Beyond; Redox Systems Regulating Lung Physiology and Disease.

Authors:  Evan A Elko; Brian Cunniff; David J Seward; Shi Biao Chia; Reem Aboushousha; Cheryl van de Wetering; Jos van der Velden; Allison Manuel; Arti Shukla; Nicholas H Heintz; Vikas Anathy; Albert van der Vliet; Yvonne M W Janssen-Heininger
Journal:  Antioxid Redox Signal       Date:  2019-04-05       Impact factor: 8.401

Review 6.  Modulating neuroinflammation and oxidative stress to prevent epilepsy and improve outcomes after traumatic brain injury.

Authors:  Clifford L Eastman; Raimondo D'Ambrosio; Thota Ganesh
Journal:  Neuropharmacology       Date:  2019-12-06       Impact factor: 5.250

7.  NOX2 is involved in CB2-mediated protection against lung ischemia-reperfusion injury in mice.

Authors:  Wei Huang; Yaqin Xiong; Yali Chen; Yan Cheng; Rurong Wang
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

Review 8.  Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases.

Authors:  Meghan C Gage; Thimmasettappa Thippeswamy
Journal:  CNS Drugs       Date:  2021-01-30       Impact factor: 5.749

9.  Meta-analysis of global and high throughput public gene array data for robust vascular gene expression discovery in chronic rhinosinusitis: Implications in controlled release.

Authors:  Nitish Khurana; Abigail Pulsipher; Hamidreza Ghandehari; Jeremiah A Alt
Journal:  J Control Release       Date:  2020-11-02       Impact factor: 9.776

Review 10.  NOX2 Activation in COVID-19: Possible Implications for Neurodegenerative Diseases.

Authors:  Cinzia Sindona; Giovanni Schepici; Valentina Contestabile; Placido Bramanti; Emanuela Mazzon
Journal:  Medicina (Kaunas)       Date:  2021-06-11       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.